RESPONSE

RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Location: CPMC (San Francisco)

Please contact: ClinicalResearch@sutterhealth.org about study RESPONSE. 

Principal Investigator

Kidist Yimam, MD

Co-Investigator(s)

Raphael Merriman, MD, Edward Holt, MD